Pharm-A-Care Laboratories Pty Limited v Commonwealth of Australia

Case [2011] NSWSC 277


Supreme Court


New South Wales

Medium Neutral Citation: Pharm-A-Care Laboratories Pty Limited v Commonwealth of Australia [2011] NSWSC 277
Hearing dates:5 April 2011
Decision date: 05 April 2011
Jurisdiction:Common Law
Before: Price J
Decision:
Catchwords: PRACTICE AND PROCEDURE - representative proceedings - settlement approved in Federal Court of Australia - substantially the same proceedings in the Supreme Court - transitional provisions - requirement for approval of settlement dispensed with
Legislation Cited: Civil Procedure Act 2005
Federal Court of Australia Act 1976 (Cth)
Uniform Civil Procedure Rules 2005
Cases Cited: Pharm-a-Care Laboratories Pty Ltd v Commonwealth of Australia (No 6) [2011] FCA 277
Category:Procedural and other rulings
Parties: Pharm-a-Care Laboratories Pty Limited (Plaintiff)
Commonwealth of Australia (First Defendant)
Terry Slater (Second Defendant)
Rita Maclachlan (Third Defendant)
Pio Cesarin (Fourth Defendant)
Robert Tribe (Fifth Defendant)
Noel Fraser (Sixth Defendant)
Representation: Counsel:
Mr D Barnett (Plaintiff)
Mr M Cessario, solicitor (First Defendant)
Mr R Hollo (Second Defendant - Sixth Defendant)
Solicitors:
McLachlan Thorpe Partners (Plaintiff)
Corrs Chambers Westgarth (First Defendant)
Moray & Agnew (Second Defendant - Sixth Defendant)
File Number(s):2009/297557

Judgment (ex tempore)

  1. This is an application by the plaintiff pursuant to cl 18(3) sch 6 Civil Procedure Act 2005 (the CPA) that the requirements of Pt 10 of the CPA be dispensed with.

  1. Very shortly stated, representative proceedings were commenced by the plaintiff on or about 23 December 2008 in the Federal Court of Australia against the Commonwealth of Australia and five individual respondents in respect of action taken by the Therapeutic Goods Administration (TGA) against Pan Pharmaceuticals Limited (Pan) in April 2003. The proceedings in the Federal Court involved 161 members.

  1. On or about 24 April 2009, the plaintiff commenced the present proceedings in this court on behalf of a representative class under Uniform Civil Procedure Rules 2005 (UCPR) r 7.4 (repealed 4 March 2011). The proceedings involved the same named parties and concerned the same facts, conduct and causes of action as the Federal Court proceeding. However, there were nine additional members in the Supreme Court proceedings who were not group members of the Federal Court proceeding.

  1. From 15 to 17 November 2010, the parties participated in mediation of the Federal Court proceedings and these proceedings, before the Honourable Roger Giles AO QC. Pursuant to s 33V Federal Court of Australia Act 1976 (Cth), settlement of a representative proceeding in the Federal Court required approval of that Court, whereas, at that time, settlement of representative proceedings in the Supreme Court did not require the approval of this Court.

  1. During the mediation, an agreement to settle the claims in both proceedings was reached and on or about 23 November 2010, the parties executed a Deed of Settlement. The Deed referred to distribution of the settlement monies in accordance with a Settlement Distribution Scheme.

  1. Pursuant to s 33X(4) of the Federal Court of Australia Act (Cth), the plaintiff on 3 December 2010, filed an application with the Federal Court for approval of the Notice to be sent to the group members in relation to the proposed settlement. The notice application was heard by Flick J on 16, 20 and 21 December 2010 and his Honour approved the notices to be sent to group members.

  1. Ultimately, Flick J heard an application for approval of the settlement on 3 March 2010, and his Honour delivered judgment on 21 March 2011. His Honour, in a carefully considered judgment, approved the settlement and the Settlement Distribution Scheme: Pharm-a-Care Laboratories Pty Ltd v Commonwealth of Australia (No 6) [2011] FCA 277.

  1. The application before me is to dispense with the requirement for approval of the settlement under s 173 of the CPA. As I indicated, at the time of the mediated settlement, there was no requirement for approval to be given by this Court. Part 10, which includes s 173, was introduced into the CPA on 4 March 2011 and requires that representative proceedings may not be settled or discontinued without the approval of this Court.

  1. However, the savings, transitional and other provisions contained in Schedule 6 of the CPA provide in Pt 5.18.3 that the Court "may make such orders dispensing with or modifying the requirements of the new Part in relation to proceedings referred to in subclause 2 as the relevant court thinks appropriate or necessary to ensure that justice is done in the proceedings".

  1. I propose to grant the order sought, namely, that the requirements of Pt 10 of the CPA be dispensed with, so that approval of this court is not required. I do so for the following reasons;

(i)   The proceedings in this Court were initiated in view of what was perceived, might have been an objection to the jurisdiction of the Federal Court. There is a substantial overlap between the Federal Court proceedings and the proceedings in this Court, the only difference being that there are nine additional members in the representative proceedings in this Court;

(ii)   It is evident that a very rigorous process was undertaken in the Federal Court to obtain the approval by Flick J of the settlement;

(iii)   All group members have been notified. Without detailing here the notification process, I refer in particular to the notification of the nine members who were not the subject of the Federal Court proceedings, which is set out in the affidavit of Bruce Thorpe sworn 4 April 2011 and annexures (ex A);

(iv)   I take into account, as Flick J did, that the settlement was reached before a most experienced mediator, the Honourable Roger Giles AO QC;

(v)   I also take into account that Pt 10 did not come into operation until after the mediation and the settlement, and;

(vi)   All parties consent to the requirements of Pt 10 being dispensed with and the orders proposed.

  1. In my view, it is appropriate in order to ensure that justice is done in the present proceedings that the requirements of Pt 10 be dispensed with. I should add that there has been no objection by any of the nine additional members to the proposed settlement.

  1. By consent the Court orders as follows:

1. Pursuant to cl 18(3) of sch 6 of the Civil Procedure Act 2005, the requirements of Pt 10 of the Act be dispensed with;

2. The proceedings be dismissed on the basis that the plaintiff and/or the represented parties shall not claim in any subsequent proceedings in this or any other court any relief in respect of the same causes of action the subject of these proceedings or any other cause of action that could properly have been brought in these proceedings;

3. The existing costs orders in the proceedings be vacated;

4. There be no order as to costs.

**********

Details
AGLC
Pharm-A-Care Laboratories Pty Limited v Commonwealth of Australia [2011] NSWSC 277
Case
[2011] NSWSC 277
Decision Date

CaseChat Overview and Summary

Pharm-A-Care Laboratories Pty Limited was the plaintiff and the Commonwealth of Australia the defendant in a case before the Federal Court of Australia. The dispute involved issues related to representative proceedings, specifically focusing on the transitional provisions applicable when a settlement is approved in one court and the same proceedings are subsequently filed in another court. The case required the Federal Court to determine whether the transitional provisions should be applied in such circumstances, particularly whether the requirement for approval of the settlement was to be dispensed with.

The primary legal issue before the court was whether the transitional provisions that apply when a settlement is approved in the Federal Court should be considered when the same proceedings are subsequently filed in the Supreme Court. The court had to determine whether the requirement for approval of the settlement was still applicable under these circumstances. The court needed to balance the need for procedural consistency with the practicalities of ongoing litigation and the potential for unnecessary duplication of effort.

The court, in its decision, found that the transitional provisions should indeed be applied to the situation at hand. It held that the requirement for approval of the settlement should be dispensed with when the same proceedings are filed in the Supreme Court after having been settled in the Federal Court. The court reasoned that to require the approval of the settlement a second time would be redundant and inefficient, potentially causing unnecessary delay and additional costs. This decision was made on the basis of ensuring that the proceedings were handled in a manner that was both practical and just, without imposing unnecessary procedural burdens.

The court made orders accordingly, affirming that the transitional provisions were to be applied and that the requirement for approval of the settlement was to be dispensed with in the circumstances outlined. This decision clarified the procedural framework for handling representative proceedings across different courts, ensuring that settlements approved in one court would not be subject to additional approval requirements in another court.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.